Summit Global Investments Buys 1,327 Shares of Amgen Inc. $AMGN

Summit Global Investments boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 41.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,509 shares of the medical research company’s stock after purchasing an additional 1,327 shares during the period. Summit Global Investments’ holdings in Amgen were worth $1,901,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wellington Altus USA Inc. grew its holdings in shares of Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares during the last quarter. Nvwm LLC raised its holdings in Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after buying an additional 66 shares during the last quarter. PFS Partners LLC raised its holdings in Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after buying an additional 42 shares during the last quarter. TOWER TRUST & INVESTMENT Co bought a new stake in Amgen during the 3rd quarter valued at $38,000. Finally, Security National Bank of Sioux City Iowa IA purchased a new stake in Amgen during the 2nd quarter valued at $36,000. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on AMGN. Guggenheim cut their price target on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a report on Tuesday, October 13th. Scotiabank upped their price objective on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. Jefferies Financial Group reiterated a “hold” rating and set a $410.00 target price on shares of Amgen in a report on Wednesday, September 23rd. Royal Bank Of Canada raised their target price on Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Finally, UBS Group raised their target price on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $389.71.

Amgen Stock Performance

NASDAQ:AMGN opened at $466.01 on Friday. The stock has a market cap of $251.94 billion, a P/E ratio of 28.96, a price-to-earnings-growth ratio of 3.41 and a beta of 0.41. The firm’s fifty day simple moving average is $419.96 and its 200 day simple moving average is $374.79. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $475.65. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the firm earned $6.02 EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts predict that Amgen Inc. will post 22.96 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen’s payout ratio is currently 62.65%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.